ADNI is a collaborative effort of scientists from around the world to help define the rate of progression of mild cognitive impairment and Alzheimer’s disease.
This project has received funding from the Innovative Medicines Initiative 2 Joint undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.